(Reuters) -Shares of Hikma Pharmaceuticals fell as much as 10% on Thursday after a strong euro prompted the group to lower margin outlook for its injectables unit, despite beating expectations for overall interim profit and maintaining annual group outlook.
The generic drugmaker now expects full-year core operating margin for the injectables business to be in the range of 32% to 33%, down from its previous forecast mid-30s percentage.
(Reporting by Unnamalai L in Bengaluru; Editing by Mrigank Dhaniwala)
Comments